ClinicalTrials.gg
CompletedNCT01312909Updated Aug 9, 2018Results posted

Smoking Cessation Study In Healthy Adolescent Smokers

A Phase 4 interventional study of Varenicline 1mg BID and Varenicline 0.5mg BID in Smoking Cessation, sponsored by Pfizer. Completed at 80 sites in 6 countries. Open to participants aged 12 Years to 19 Years. Per ClinicalTrials.gov, last updated 2018-08-09.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
12 Years to 19 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.

Enrollment
40th of 110
312 · median 209
Started
2011
with 10 others
Phase 4
47 of 110
3 open now
Registered
55th of 110
by date
Lead sponsor
26 of 110
Pfizer

Among the 110 studies testing varenicline in Smoking Cessation, this one is the 40th largest by enrollment, is one of 11 that started in 2011, is one of 47 in phase 4, and was the 55th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 12 Years to 19 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing varenicline in Smoking Cessation, or all of them as a file.
02

Study summary

The study is designed to see if varenicline combined with age appropriate (adolescent) smoking cessation counseling will help teens quit smoking.

03

Conditions studied

  • Smoking Cessation

Browse trials for

Keywords

  • smoking cessation in adolescents
04

Who can participate

Ages eligible
12 Years to 19 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects between the ages of 12 and 19, inclusive.
  • Subjects smoking at least an average of 5 cigarettes per day, motivated to stop smoking,
  • Subjects must have at least one prior failed attempt to quit smoking.

Exclusion criteria

Exclusion Criteria:

  • Subjects with history, current diagnosis, or treatment of major depression disorder, anxiety disorders, panic disorder, hostility or aggression disorder, perceptual/thinking disturbances, mania, psychosis, bipolar disorder, personality disorder, eating disorder or severe emotional problems (in the past year).
  • Subjects with a prior suicide attempt: subjects hospitalized within the past 12 months due to suicidal ideation or suicidal behavior; subjects considered to have serious suicidal ideation or suicidal behavior in the past 12 months; active suicidal ideation or behavior identified at the screening or baseline visit.
  • Evidence of alcohol and substance abuse/dependence (other than nicotine) within 3 months prior to screening.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
312 participants (actual)

Study arms

  • Experimental
    Varenicline 1mg BID

    Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52

    Drug: Varenicline 1mg BID

  • Experimental
    Varenicline 0.5mg BID

    Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52

    Drug: Varenicline 0.5mg BID

  • Placebo comparator
    Placebo

    Oral placebo for twelve weeks,follow-up through Week 52

    Drug: Placebo

Interventions

  • Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52

  • Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52

  • DrugPlacebo

    Oral placebo for twelve weeks,follow-up through Week 52

06

What researchers measure

Primary outcomes

  1. 4-Week Continuous Abstinence Rate: Percentage of Participants Who Remained Abstinent From Week 9 Through Week 12

    The percentage of participants who, at each visit from Week 9 through Week 12, reported no smoking and no use of other nicotine-containing products since the last study visit (on the Nicotine Use Inventory) and at each of these visits were confirmed to have quit based on urine cotinine less than 200 nanograms/milliliter (ng/mL).

    Time frame: Week 9 through Week 12

Secondary outcomes

  1. Percentage of Participants With 7-Day Point Prevalence of Smoking Abstinence at Weeks 12, 24 and 52

    The percentage of participants who reported no smoking and no use of other nicotine-containing products (treatment phase) or tobacco products (non-treatment phase) on the Nicotine Use Inventory in the 7 days prior to the study visits or telephone contacts at Week 12,24 and 52.

    Time frame: Weeks 12, 24 and 52

  2. Daily Number of Cigarettes Smoked at Baseline

    The average number of cigarettes smoked per day in the past 7 days reported at the baseline visit.

    Time frame: Baseline

  3. Change From Baseline in Daily Number of Cigarettes Smoked at Weeks 12, 24, and 52

    The reduction in the number of the cigarettes smoked was calculated by subtracting the reported average number of cigarettes smoked per day in the past 7 days at Weeks 12, 24 and 52 from the average number of cigarettes smoked per day in the past 7 days reported at the baseline visit.

    Time frame: Baseline, Weeks 12, 24, and 52

  4. Continuous Abstinence Rate: Percentage of Participants Who Remained Abstinent From Week 9 Through Week 24 and Week 52

    The percentage of participants who, at each visit from Week 9 to 52 (inclusive), reported no smoking and no use of other nicotine-containing products (Weeks 9-12) or tobacco products (Weeks 13-52) since the last study visit/last contact (on the Nicotine Use Inventory) and at any of the study visits were confirmed to have quit based on urine cotinine less than 200 ng/mL.

    Time frame: Week 9 through Week 24; Week 9 through Week 52

Other outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both non-serious AEs and SAEs.

    Time frame: First dose up to last dose (up-to Week 12) plus 30 days

  2. Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent were events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to drug Varenicline was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category. An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both non-serious AEs and SAEs.

    Time frame: First dose up to last dose (up-to Week 12) plus 30 days

  3. Number of Participants With Treatment-Emergent Neuropsychiatric Adverse Event Elicited by Neuropsychiatric Adverse Event Interview (NAEI)

    An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE: AE causing: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent/significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Solicited AEs collected by semi-structured NAEI inquiring about AEs: depression, anxiety, delusions, hallucinations, paranoia, psychosis, mania, panic, agitation, dissociative states, feeling abnormal, hostility, aggression and homicidal ideation. If a participant had a positive response to any item on the NAEI, investigator determined if it met criteria AE criteria.

    Time frame: First dose up to last dose (up-to Week 12) plus 30 days

  4. Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment (C-CASA) categories);was an interview-based instrument to systematically assess suicidal ideation and suicidal behavior.C-SSRS assessed whether participant experienced any of the following:completed suicide;suicide attempt(response of "Yes" on "actual attempt");preparatory acts toward imminent suicidal behavior ("Yes" on "preparatory acts or behavior","aborted attempt" or "interrupted attempt"),suicidal ideation ("Yes" on "wish to be dead","non-specific active suicidal thoughts","active suicidal ideation with methods without intent to act or some intent to act,without specific plan or with specific plan and intent,any self-injurious behavior with no suicidal intent ("Yes" on "Has participant engaged in non-suicidal self-injurious behavior").Here,number of participants with positive response (response of "yes") to suicidal behavior or/and Ideation,any non-suicidal self-injurious behavior were reported.

    Time frame: Screening, Baseline, Week 1 up to Week 12 (treatment-emergent [TE]), thereafter up to Week 52 (last follow-up [FU])

  5. Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Anxiety (HADS-A) Total Scores at Specified Time-points

    The HADS is a self-administered questionnaire measuring anxiety. Hospital Anxiety and Depression Scale Anxiety subscale (HADS-A) consisted of 7 items that were assessed on a scale of 0 = no anxiety to 3 = severe feeling of anxiety. Total HADS-A subscale score range from 0 = no anxiety to 21 = severe anxiety; higher scores indicated more severe anxiety.

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 20, 28, 36, 44, and 52

  6. Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Scores - Depression Total Score at Specified Time-Points

    Hospital Anxiety and Depression Scale Depression subscale (HADS-D) consists of 7 items that were assessed on a scale of 0 = no depression to 3 = severe feeling of depression. Total HADS-D subscale score range from 0 = no depression to 21 = severe feeling of depression; higher scores indicated a greater intensity of depression.

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 20, 28, 36, 44, and 52

  7. Number of Participants With Laboratory Abnormalities

    Criteria for laboratory abnormalities: Lymphocytes Absolute (Abs), Lymphocytes percentage (%), Total Neutrophils (Abs), Neutrophils %: \<0.8\*LLN or \>1.2\*ULN; Basophils (Abs), Basophils %Eosinophils (Abs), Eosinophils %, Monocytes (Abs), Monocytes %:\> 1.2\*ULN; Total Bilirubin milligram per deciliter (mg/dl) \>1.5\*ULN; alanine aminotransferase: \>3.0\*ULN; Blood urea nitrogen, Creatinine: \>1.3\*ULN; Uric acid :\> 1.2\*ULN.

    Time frame: Baseline up to Week 12

  8. Change From Baseline in Blood Pressure (BP) at Week 12

    Measurement of BP included supine and sitting systolic BP, standing systolic BP, supine and sitting diastolic BP and standing diastolic BP. Blood pressure was taken after participants rested in a sitting position for 5 minutes. BP was recorded after participants had been supine for approximately 5 minutes, and then orthostatic blood pressure was recorded immediately when the participant stood.

    Time frame: Baseline, Week 12

  9. Change From Baseline in Pulse Rate at Week 12

    Measurement of pulse rate included supine, sitting and standing pulse rate. Pulse rate was taken after participants rested in a sitting position for 5 minutes. Pulse rate was recorded after participants had been supine for approximately 5 minutes and then immediately upon standing.

    Time frame: Baseline, Week 12

07

Results

Posted Jun 28, 2018

Participant flow

Participant flow — Overall Study
MilestoneVarenicline High DoseVarenicline Low DosePlacebo
Started109103100
Treated10810099
Completed676753
Not completed423647
Withdrew: Randomized but not treated131
Withdrew: Adverse event103
Withdrew: Protocol violation202
Withdrew: Other9611
Withdrew: Withdrawal by subject8107
Withdrew: Lost to follow-up211720
Withdrew: Insufficient clinical response001
Withdrew: Entrance criteria not met002

Outcome measures

Primary4-Week Continuous Abstinence Rate: Percentage of Participants Who Remained Abstinent From Week 9 Through Week 12

The percentage of participants who, at each visit from Week 9 through Week 12, reported no smoking and no use of other nicotine-containing products since the last study visit (on the Nicotine Use Inventory) and at each of these visits were confirmed to have quit based on urine cotinine less than 200 nanograms/milliliter (ng/mL).

Time frame:
Week 9 through Week 12
Reported as:
Number · percentage of participants
4-Week Continuous Abstinence Rate: Percentage of Participants Who Remained Abstinent From Week 9 Through Week 12
percentage of participantsVarenicline High DoseVarenicline Low DosePlacebo
4-Week Continuous Abstinence Rate: Percentage of Participants Who Remained Abstinent From Week 9 Through Week 1220.227.218.0
Statistical analysis
  • Varenicline High Dose vs Placebo · Regression, Logistic · p = 0.6337 (Threshold for significance at 0.05 level.) · Odds ratio (or): 1.18 · 95% CI 0.59 to 2.37
  • Varenicline Low Dose vs Placebo · Regression, Logistic · p = 0.1114 (Threshold for significance at 0.05 level.) · Odds ratio (or): 1.73 · 95% CI 0.88 to 3.39
SecondaryPercentage of Participants With 7-Day Point Prevalence of Smoking Abstinence at Weeks 12, 24 and 52

The percentage of participants who reported no smoking and no use of other nicotine-containing products (treatment phase) or tobacco products (non-treatment phase) on the Nicotine Use Inventory in the 7 days prior to the study visits or telephone contacts at Week 12,24 and 52.

Time frame:
Weeks 12, 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants With 7-Day Point Prevalence of Smoking Abstinence at Weeks 12, 24 and 52
percentage of participantsVarenicline High DoseVarenicline Low DosePlacebo
Week 1231.237.923.0
Week 2431.235.923.0
Week 5228.435.020.0
Statistical analysis
  • Varenicline High Dose vs Placebo · Regression, Logistic · p = 0.5793 · Odds ratio (or): 1.21 · 95% CI 0.62 to 2.38Odds ratios and p-values were obtained from separate logistic regression models of treatment, pooled center, age strata and body weight strata.
  • Varenicline Low Dose vs Placebo · Regression, Logistic · p = 0.0932 · Odds ratio (or): 1.79 · 95% CI 0.91 to 3.51Odds ratios and p-values were obtained from separate logistic regression models of treatment, pooled center, age strata and body weight strata.
  • Varenicline High Dose vs Placebo · Regression, Logistic · p = 0.5647 · Odds ratio (or): 1.23 · 95% CI 0.61 to 2.50Odds ratios and p-values were obtained from separate logistic regression models of treatment, pooled center, age strata and body weight strata.
  • Varenicline Low Dose vs Placebo · Regression, Logistic · p = 0.2917 · Odds ratio (or): 1.46 · 95% CI 0.72 to 2.96Odds ratios and p-values were obtained from separate logistic regression models of treatment, pooled center, age strata and body weight strata.
  • Varenicline High Dose vs Placebo · Regression, Logistic · p = 0.5616 · Odds ratio (or): 1.25 · 95% CI 0.58 to 2.69Odds ratios and p-values were obtained from separate logistic regression models of treatment, pooled center, age strata and body weight strata.
  • Varenicline Low Dose vs Placebo · Regression, Logistic · p = 0.1300 · Odds ratio (or): 1.79 · 95% CI 0.84 to 3.78Odds ratios and p-values were obtained from separate logistic regression models of treatment, pooled center, age strata and body weight strata.
SecondaryDaily Number of Cigarettes Smoked at Baseline

The average number of cigarettes smoked per day in the past 7 days reported at the baseline visit.

Time frame:
Baseline
Reported as:
Mean · cigarettes smoked per day
Daily Number of Cigarettes Smoked at Baseline
cigarettes smoked per dayVarenicline High DoseVarenicline Low DosePlacebo
Daily Number of Cigarettes Smoked at Baseline10.68 ± 0.6249.56 ± 0.5309.57 ± 0.531
SecondaryChange From Baseline in Daily Number of Cigarettes Smoked at Weeks 12, 24, and 52

The reduction in the number of the cigarettes smoked was calculated by subtracting the reported average number of cigarettes smoked per day in the past 7 days at Weeks 12, 24 and 52 from the average number of cigarettes smoked per day in the past 7 days reported at the baseline visit.

Time frame:
Baseline, Weeks 12, 24, and 52
Reported as:
Least squares mean · cigarettes smoked per day
Change From Baseline in Daily Number of Cigarettes Smoked at Weeks 12, 24, and 52
cigarettes smoked per dayVarenicline High DoseVarenicline Low DosePlacebo
Change at Week 12-8.56 ± 0.43-8.20 ± 0.44-8.01 ± 0.46
Change at Week 24-6.93 ± 0.44-7.31 ± 0.45-6.59 ± 0.48
Change at Week 52-6.80 ± 0.45-7.74 ± 0.46-6.98 ± 0.48
Statistical analysis
  • Varenicline High Dose vs Placebo · Longitudinal repeated measures model · p = 0.3540 · Least square (ls) mean difference: -0.54 · 95% CI -1.69 to 0.60
  • Varenicline Low Dose vs Placebo · Longitudinal repeated measures model · p = 0.7574 · Ls mean difference: -0.18 · 95% CI -1.35 to 0.98
  • Varenicline High Dose vs Placebo · Longitudinal repeated measures model · p = 0.5676 · Ls mean difference: -0.34 · 95% CI -1.53 to 0.84
  • Varenicline Low Dose vs Placebo · Longitudinal repeated measures model · p = 0.2356 · Ls mean difference: -0.72 · 95% CI -1.92 to 0.47
  • Varenicline High Dose vs Placebo · Longitudinal repeated measures model · p = 0.7730 · Ls mean difference: 0.18 · 95% CI -1.03 to 1.38
  • Varenicline Low Dose vs Placebo · Longitudinal repeated measures model · p = 0.2166 · Ls mean difference: -0.77 · 95% CI -1.99 to 0.45
SecondaryContinuous Abstinence Rate: Percentage of Participants Who Remained Abstinent From Week 9 Through Week 24 and Week 52

The percentage of participants who, at each visit from Week 9 to 52 (inclusive), reported no smoking and no use of other nicotine-containing products (Weeks 9-12) or tobacco products (Weeks 13-52) since the last study visit/last contact (on the Nicotine Use Inventory) and at any of the study visits were confirmed to have quit based on urine cotinine less than 200 ng/mL.

Time frame:
Week 9 through Week 24; Week 9 through Week 52
Reported as:
Number · percentage of participants
Continuous Abstinence Rate: Percentage of Participants Who Remained Abstinent From Week 9 Through Week 24 and Week 52
percentage of participantsVarenicline High DoseVarenicline Low DosePlacebo
Week 9 through Week 2410.124.313.0
Week 9 through Week 528.320.49.0
Statistical analysis
  • Varenicline High Dose vs Placebo · Regression, Logistic · p = 0.6133 · Odds ratio (or): 0.80 · 95% CI 0.34 to 1.90
  • Varenicline Low Dose vs Placebo · Regression, Logistic · p = 0.0335 · Odds ratio (or): 2.26 · 95% CI 1.07 to 4.79
  • Varenicline High Dose vs Placebo · Regression, Logistic · p = 0.9874 · Odds ratio (or): 0.99 · 95% CI 0.37 to 2.65
  • Varenicline Low Dose vs Placebo · Regression, Logistic · p = 0.0188 · Odds ratio (or): 2.79 · 95% CI 1.19 to 6.55
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both non-serious AEs and SAEs.

Time frame:
First dose up to last dose (up-to Week 12) plus 30 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs)
ParticipantsVarenicline High DoseVarenicline Low DosePlacebo
Number of Participants With Treatment-Emergent Adverse Events (AEs)655352
Other pre-specifiedNumber of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)

Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent were events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to drug Varenicline was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category. An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both non-serious AEs and SAEs.

Time frame:
First dose up to last dose (up-to Week 12) plus 30 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)
ParticipantsVarenicline High DoseVarenicline Low DosePlacebo
Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)462827
Other pre-specifiedNumber of Participants With Treatment-Emergent Neuropsychiatric Adverse Event Elicited by Neuropsychiatric Adverse Event Interview (NAEI)

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE: AE causing: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent/significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Solicited AEs collected by semi-structured NAEI inquiring about AEs: depression, anxiety, delusions, hallucinations, paranoia, psychosis, mania, panic, agitation, dissociative states, feeling abnormal, hostility, aggression and homicidal ideation. If a participant had a positive response to any item on the NAEI, investigator determined if it met criteria AE criteria.

Time frame:
First dose up to last dose (up-to Week 12) plus 30 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Neuropsychiatric Adverse Event Elicited by Neuropsychiatric Adverse Event Interview (NAEI)
ParticipantsVarenicline High DoseVarenicline Low DosePlacebo
Neuropsychiatric AEs181112
Neuropsychiatric SAEs000
Other pre-specifiedNumber of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)

The C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment (C-CASA) categories);was an interview-based instrument to systematically assess suicidal ideation and suicidal behavior.C-SSRS assessed whether participant experienced any of the following:completed suicide;suicide attempt(response of "Yes" on "actual attempt");preparatory acts toward imminent suicidal behavior ("Yes" on "preparatory acts or behavior","aborted attempt" or "interrupted attempt"),suicidal ideation ("Yes" on "wish to be dead","non-specific active suicidal thoughts","active suicidal ideation with methods without intent to act or some intent to act,without specific plan or with specific plan and intent,any self-injurious behavior with no suicidal intent ("Yes" on "Has participant engaged in non-suicidal self-injurious behavior").Here,number of participants with positive response (response of "yes") to suicidal behavior or/and Ideation,any non-suicidal self-injurious behavior were reported.

Time frame:
Screening, Baseline, Week 1 up to Week 12 (treatment-emergent [TE]), thereafter up to Week 52 (last follow-up [FU])
Reported as:
Count of participants · Participants
Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)
ParticipantsVarenicline High DoseVarenicline Low DosePlacebo
Screening:Suicidal Behavior or/and Ideation232
Screening:Suicidal Ideation232
Screening: Wish to be Dead222
Screening: Non-Specific Active Suicidal Thoughts112
Screen:Self Injurious Behavior, no Suicidal Intent332
TE:Suicidal Behavior or/and Ideation101
TE:Suicidal Ideation101
TE: Wish to be Dead101
TE: Non-Specific Active Suicidal Thoughts001
TE:Self Injurious Behavior, no Suicidal Intent001
Other pre-specifiedChange From Baseline in Hospital Anxiety and Depression Scale (HADS) - Anxiety (HADS-A) Total Scores at Specified Time-points

The HADS is a self-administered questionnaire measuring anxiety. Hospital Anxiety and Depression Scale Anxiety subscale (HADS-A) consisted of 7 items that were assessed on a scale of 0 = no anxiety to 3 = severe feeling of anxiety. Total HADS-A subscale score range from 0 = no anxiety to 21 = severe anxiety; higher scores indicated more severe anxiety.

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 20, 28, 36, 44, and 52
Reported as:
Mean · units on a scale
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Anxiety (HADS-A) Total Scores at Specified Time-points
units on a scaleVarenicline High DoseVarenicline Low DosePlacebo
Baseline2.4 ± 2.051.9 ± 2.062.3 ± 2.26
Change at Week 1-0.6 ± 1.86-0.5 ± 1.53-0.3 ± 1.91
Change at Week 2-1.1 ± 1.95-0.7 ± 1.90-0.5 ± 2.18
Change at Week 3-1.2 ± 1.85-0.8 ± 1.96-1.0 ± 2.09
Change at Week 4-1.5 ± 1.83-0.9 ± 2.31-0.9 ± 2.21
Change at Week 5-1.3 ± 2.03-1.0 ± 2.12-1.2 ± 2.19
Change at Week 6-1.5 ± 1.91-1.0 ± 2.25-1.2 ± 2.31
Change at Week 7-1.6 ± 2.13-1.1 ± 2.41-1.2 ± 2.39
Change at Week 8-1.5 ± 2.11-1.1 ± 2.20-1.3 ± 1.99
Change at Week 9-1.4 ± 2.17-1.2 ± 2.35-1.1 ± 2.13
Change at Week 10-1.4 ± 2.07-1.2 ± 2.44-1.1 ± 2.34
Change at Week 11-1.4 ± 2.00-1.2 ± 2.23-1.3 ± 2.12
Change at Week 12-1.4 ± 2.07-1.3 ± 2.31-1.2 ± 2.15
Change at Week 13-1.5 ± 2.13-1.2 ± 2.17-1.2 ± 2.33
Change at Week 14-1.4 ± 2.33-1.2 ± 2.53-1.2 ± 2.19
Change at Week 15-1.7 ± 2.09-1.3 ± 2.43-1.0 ± 3.35
Change at Week 16-1.6 ± 2.16-1.2 ± 2.44-1.1 ± 2.54
Change at Week 20-1.5 ± 2.28-1.2 ± 2.31-1.3 ± 2.21
Change at Week 28-1.5 ± 2.54-1.2 ± 2.46-1.2 ± 2.38
Change at Week 36-1.4 ± 2.42-1.2 ± 2.51-1.3 ± 2.03
Change at Week 44-1.8 ± 2.21-1.2 ± 2.34-1.0 ± 1.90
Change at Week 52-1.6 ± 2.20-1.1 ± 2.39-1.5 ± 2.06
Other pre-specifiedChange From Baseline in Hospital Anxiety and Depression Scale (HADS) Scores - Depression Total Score at Specified Time-Points

Hospital Anxiety and Depression Scale Depression subscale (HADS-D) consists of 7 items that were assessed on a scale of 0 = no depression to 3 = severe feeling of depression. Total HADS-D subscale score range from 0 = no depression to 21 = severe feeling of depression; higher scores indicated a greater intensity of depression.

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 20, 28, 36, 44, and 52
Reported as:
Mean · units on a scale
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Scores - Depression Total Score at Specified Time-Points
units on a scaleVarenicline High DoseVarenicline Low DosePlacebo
Baseline1.5 ± 1.931.4 ± 1.791.4 ± 1.83
Change at Week 1-0.4 ± 1.43-0.2 ± 1.180.1 ± 1.61
Change at Week 2-0.5 ± 1.57-0.2 ± 1.65-0.1 ± 1.80
Change at Week 3-0.5 ± 1.39-0.3 ± 1.55-0.3 ± 1.79
Change at Week 4-0.7 ± 1.39-0.3 ± 1.79-0.4 ± 2.00
Change at Week 5-0.6 ± 1.66-0.3 ± 1.97-0.3 ± 1.88
Change at Week 6-0.6 ± 1.85-0.4 ± 1.60-0.5 ± 1.83
Change at Week 7-0.7 ± 1.52-0.5 ± 1.91-0.4 ± 2.13
Change at Week 8-0.8 ± 1.87-0.5 ± 1.80-0.5 ± 1.80
Change at Week 9-0.8 ± 1.63-0.5 ± 1.85-0.5 ± 2.30
Change at Week 10-0.9 ± 1.67-0.7 ± 1.63-0.4 ± 2.77
Change at Week 11-0.7 ± 1.53-0.9 ± 1.66-0.5 ± 2.11
Change at Week 12-0.7 ± 1.79-0.7 ± 1.72-0.6 ± 2.11
Change at Week 13-0.6 ± 2.16-0.7 ± 1.79-0.7 ± 1.95
Change at Week 14-0.8 ± 1.96-0.6 ± 1.84-0.5 ± 2.22
Change at Week 15-0.8 ± 1.83-0.8 ± 1.84-0.3 ± 3.26
Change at Week 16-0.6 ± 2.09-0.6 ± 2.08-0.2 ± 2.79
Change at Week 20-0.8 ± 1.71-0.8 ± 1.84-0.6 ± 2.24
Change at Week 28-0.9 ± 1.63-0.8 ± 1.90-0.5 ± 2.40
Change at Week 36-0.7 ± 2.19-0.8 ± 1.77-0.4 ± 2.40
Change at Week 44-0.9 ± 1.93-0.9 ± 1.78-0.3 ± 2.44
Change at Week 52-0.7 ± 1.81-0.8 ± 1.67-0.6 ± 2.02
Other pre-specifiedNumber of Participants With Laboratory Abnormalities

Criteria for laboratory abnormalities: Lymphocytes Absolute (Abs), Lymphocytes percentage (%), Total Neutrophils (Abs), Neutrophils %: \<0.8\*LLN or \>1.2\*ULN; Basophils (Abs), Basophils %Eosinophils (Abs), Eosinophils %, Monocytes (Abs), Monocytes %:\> 1.2\*ULN; Total Bilirubin milligram per deciliter (mg/dl) \>1.5\*ULN; alanine aminotransferase: \>3.0\*ULN; Blood urea nitrogen, Creatinine: \>1.3\*ULN; Uric acid :\> 1.2\*ULN.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsVarenicline High DoseVarenicline Low DosePlacebo
Number of Participants With Laboratory Abnormalities353326
Other pre-specifiedChange From Baseline in Blood Pressure (BP) at Week 12

Measurement of BP included supine and sitting systolic BP, standing systolic BP, supine and sitting diastolic BP and standing diastolic BP. Blood pressure was taken after participants rested in a sitting position for 5 minutes. BP was recorded after participants had been supine for approximately 5 minutes, and then orthostatic blood pressure was recorded immediately when the participant stood.

Time frame:
Baseline, Week 12
Reported as:
Median · millimeters of mercury (mmHg)
Change From Baseline in Blood Pressure (BP) at Week 12
millimeters of mercury (mmHg)Varenicline High DoseVarenicline Low DosePlacebo
Supine Systolic BP:Baseline115.0 (85 to 164)114.0 (92 to 136)109.0 (95 to 142)
Supine Systolic BP:Change at Week 120.0 (-33 to 25)0.0 (-32 to 31)0.0 (-35 to 43)
Sitting Systolic BP:Baseline117.0 (90 to 148)115.0 (95 to 139)113.0 (95 to 135)
Sitting Systolic BP:Change at Week 12-1.0 (-24 to 31)0.0 (-30 to 28)2.0 (-28 to 28)
Standing Systolic BP:Baseline116.0 (88 to 157)115.0 (92 to 155)112.0 (90 to 136)
Standing Systolic BP:Change at Week 120.0 (-30 to 40)0.0 (-21 to 53)3.0 (-18 to 47)
Supine Diastolic BP:Baseline69.0 (45 to 99)66.0 (45 to 84)65.0 (50 to 90)
Supine Diastolic BP:Change at Week 120.0 (-26 to 17)0.0 (-20 to 22)0.0 (-35 to 21.0)
Sitting Diastolic BP:Baseline72.0 (50 to 94)70.0 (38 to 92)69.0 (47 to 87)
Sitting Diastolic BP:Change at Week 120.0 (-20 to 28)-1.0 (-35 to 23)1.0 (-18 to 22)
Standing Diastolic BP:Baseline73.0 (57 to 106)72.0 (55 to 99)70.0 (50 to 92)
Standing Diastolic BP:Change at Week 120.0 (-28 to 22)-1.0 (-43 to 23)2.0 (-21 to 20)
Other pre-specifiedChange From Baseline in Pulse Rate at Week 12

Measurement of pulse rate included supine, sitting and standing pulse rate. Pulse rate was taken after participants rested in a sitting position for 5 minutes. Pulse rate was recorded after participants had been supine for approximately 5 minutes and then immediately upon standing.

Time frame:
Baseline, Week 12
Reported as:
Median · beats per minute (bpm)
Change From Baseline in Pulse Rate at Week 12
beats per minute (bpm)Varenicline High DoseVarenicline Low DosePlacebo
Supine Pulse Rate:Baseline75.0 (50 to 111)72.0 (50 to 105)72.0 (54 to 113)
Supine Pulse Rate:Change at Week 120.0 (-32 to 44)1.0 (-23 to 23)3.0 (-30 to 29)
Sitting Pulse Rate:Baseline75.0 (58 to 118)75.0 (48 to 113)77.0 (58 to 115)
Sitting Pulse Rate:Change at Week 12-1.0 (-22 to 25)0.0 (-33 to 30)1.0 (-43 to 36)
Standing Pulse Rate:Baseline84.0 (61 to 139)85.0 (61 to 119)85.0 (63 to 122)
Standing Pulse Rate:Change at Week 121.0 (-35 to 44)-3.0 (-25 to 32)-3.0 (-53 to 44)

Adverse events

Collected over First dose up to last dose (up-to Week 12) plus 30 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Varenicline High Dose0/108 (0%)3/108 (2.8%)65/108 (60.2%)
Varenicline Low Dose0/100 (0%)1/100 (1%)53/100 (53%)
Placebo0/99 (0%)1/99 (1%)51/99 (51.5%)
Most frequent serious events
Most frequent serious events
EventVarenicline High DoseVarenicline Low DosePlacebo
SalpingitisInfections and infestations0/1080/1001/99
Bile duct stoneHepatobiliary disorders0/1081/1000/99
Cholecystitis acuteHepatobiliary disorders0/1081/1000/99
Campylobacter gastroenteritisInfections and infestations1/1080/1000/99
LaryngitisInfections and infestations1/1080/1000/99
Adjustment disorder with mixed disturbance of emotion and conductPsychiatric disorders1/1080/1000/99
Most frequent other events
Showing 10 of 139
Most frequent other events
EventVarenicline High DoseVarenicline Low DosePlacebo
NauseaGastrointestinal disorders26/10819/10012/99
VomitingGastrointestinal disorders14/1082/1002/99
HeadacheNervous system disorders14/1085/1008/99
AgitationPsychiatric disorders9/1085/1005/99
Abnormal dreamsPsychiatric disorders8/1085/1004/99
AnxietyPsychiatric disorders6/1084/1007/99
DizzinessNervous system disorders6/1087/1003/99
HostilityPsychiatric disorders7/1083/1004/99
Upper respiratory tract infectionInfections and infestations6/1085/1002/99
NasopharyngitisInfections and infestations4/1083/1005/99

Baseline characteristics

The safety analysis set included all participants who took at least one dose of randomized study medication, including partial doses.

Age, Continuous
Age, Continuous(years)Varenicline High DoseVarenicline Low DosePlaceboTotal
Mean16.0 ± 2.016.0 ± 1.715.8 ± 1.815.9 ± 1.8
Sex: Female, Male
Sex: Female, Male(Participants)Varenicline High DoseVarenicline Low DosePlaceboTotal
Female383736111
Male706363196
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Varenicline High DoseVarenicline Low DosePlaceboTotal
White817374228
Black99523
Asian16181953
Other2013
08

Study locations

80 sites
  • IICR, Inc. (DBA: International Institute of Clinical Research)
    Ozark, Alabama 36360, United States
  • Dedicated Clinical Research
    Goodyear, Arizona 85395, United States
  • Arkansas Psychiatric Clinic Clinical Research Trials, P.A.
    Little Rock, Arkansas 72211, United States
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Omega Clinical Trials, LLC
    La Habra, California 90631, United States
  • Synergy Clinical Research Center
    National City, California 91950, United States
  • Pacific Research Partners, LLC
    Oakland, California 94607, United States
  • North County Clinical Research
    Oceanside, California 92054, United States
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • MCB Clinical Research Centers
    Colorado Springs, Colorado 80910, United States
  • Western Affiliated Research Institute
    Denver, Colorado 80209, United States
  • Connecticut Mental Health Center
    New Haven, Connecticut 06511, United States
  • Yale University, SATU
    New Haven, Connecticut 06511, United States
  • Yale University
    New Haven, Connecticut 06520, United States
  • Avail Clinical Research, LLC
    DeLand, Florida 32720, United States
  • Hope Clinical Research
    Kissimmee, Florida 34741, United States
  • Florida Clinical Research Center, LLC
    Maitland, Florida 32751, United States
  • Pharmax Research Clinic, Inc.
    Miami, Florida 33126, United States
  • L & L Research Choices
    Miami, Florida 33144, United States
  • Bravo Health Care Center
    North Bay Village, Florida 33141, United States
  • Medical Research Group of Central Florida
    Orange City, Florida 32763, United States
  • Comprehensive Clinical Development Inc.
    Saint Petersburg, Florida 33716, United States
  • Barney Greenspan, Ph.D
    Meridian, Idaho 83646, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • Midwest Behavioral Health
    Evansville, Indiana 47715, United States
  • Goldpoint Clinical Research, LLC
    Indianapolis, Indiana 46260, United States
  • Pedia Research, LLC
    Newburgh, Indiana 47630, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67207, United States
  • Kentucky Pediatric/Adult Research
    Bardstown, Kentucky 40004, United States
  • Central Kentucky Research Associates, Inc.
    Lexington, Kentucky 40509, United States
  • Pedia Research, LLC
    Owensboro, Kentucky 42301, United States
  • Research Integrity, LLC
    Owensboro, Kentucky 42303, United States
  • Louisiana Research Associates, Inc
    New Orleans, Louisiana 70114, United States
  • Adams Clinical Trials, LLC
    Watertown, Massachusetts 02472, United States
  • Rochester Center for Behavioral Medicine
    Rochester Hills, Michigan 48307, United States
  • The Center for Pharmaceutical Research, P.C.
    Kansas City, Missouri 64114, United States
  • Psychiatric Care & Research Center
    O'Fallon, Missouri 63368, United States
  • Mid-America Clinical Research, LLC
    Saint Louis, Missouri 63109, United States
  • Premier Psychiatric Research Institute, LLC
    Lincoln, Nebraska 68526, United States
  • Wake Internal Medicine Consultants, Inc
    Raleigh, North Carolina 27612, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • PMG Research of Wilmington, LLC
    Wilmington, North Carolina 28401, United States
  • Neuro-Behavioral Clinical Research, Inc.
    Canton, Ohio 44718, United States
  • Neurology & Neuroscience Center of Ohio
    Toledo, Ohio 43623, United States
  • Cutting Edge Research Group
    Oklahoma City, Oklahoma 73116, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • FutureSearch Trials of Dallas, L.P.
    Dallas, Texas 75231, United States
  • Insite Clinical Research, LLC
    DeSoto, Texas 75115, United States
  • R/D Clinical Research, Inc.
    Lake Jackson, Texas 77566, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • Thomas Murray DeMoor, MD
    San Antonio, Texas 78230, United States
  • Clinical Research Partners, LLC
    Richmond, Virginia 23235, United States
  • Eastside Therapeutic Resource
    Kirkland, Washington 98033, United States
  • Zain Research, LLC
    Richland, Washington 99352, United States
  • Dean Foundation for Health Research and Education
    Middleton, Wisconsin 53562, United States
  • Kids Clinic
    Ajax, Ontario L1Z 0M1, Canada
  • SKDS Research Inc.
    New Market, Ontario L3Y 5G8, Canada
  • Private Practice of Robert J. Camargo
    Newmarket, Ontario L3Y 5G8, Canada
  • LTD" Rustavi Psychological Health Center"
    Rustavi, 3700, Georgia
  • Hallym University Sacred Heart Hospital
    Anyang-si, Gyeonggi-do 14068, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, Korea, Republic of
  • The Catholic University of Korea St. Vincent Hospital
    Suwon-si, Gyeonggi-do 442 723, Korea, Republic of
  • Keimyung University Dongsan Hospital
    Daegu, 41931, Korea, Republic of
  • Leningrad Regional Dispensary of Narcology
    Village Novoe Devyatkino, Leningrad Region 188661, Russian Federation
  • GBUZ City childrens out-patient clinic # 10 of Moscow
    Moscow, 119331, Russian Federation
  • GOBUZ Murmansk Regional Narcology Dispensary
    Murmansk, 183036, Russian Federation
  • LLC City Neurological Center "Sibneuromed"
    Novosibirsk, 630091, Russian Federation
  • LLC " Alliance Biomedical - Russian Group"
    Saint-Petersburg, 190068, Russian Federation
  • LLC Medical Technologies
    Saint-Petersburg, 191025, Russian Federation
  • FSBI V.M.Bekhterev National Research Medical Center for Psychiatry and Neurology of RF MoH
    Saint-Petersburg, 192019, Russian Federation
  • LLC Medical Technologies
    Saint-Petersburg, 192148, Russian Federation
  • First St. Petersburg State Medical University
    Saint-Petersburg, 197022, Russian Federation
  • GBUZ Samara Regional Childrens Health camp Yunost
    Samara, 443031, Russian Federation
  • Kaohsiung Veterans General Hospital
    Kaohsiung City, 81362, Taiwan
  • Far Eastern Memorial Hospital
    New Taipei City, 220, Taiwan
  • Taipei Medical University Shuang Ho Hospital
    New Taipei City, 23561, Taiwan
  • China Medical University Hospital
    Taichung city, 40447, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • Taipei Veterans General Hospital
    Taipei City, 11217, Taiwan
09

References and documents

Publications

  • Fediuk DJ, Sweeney K, Sahasrabudhe V, McRae T, Byon W. Population pharmacokinetics and exposure-response analyses of varenicline in adolescent smokers. CPT Pharmacometrics Syst Pharmacol. 2021 Jul;10(7):769-781. doi: 10.1002/psp4.12645. Epub 2021 Jun 17. PubMed 34062053 ↗
  • Gray KM, Rubinstein ML, Prochaska JJ, DuBrava SJ, Holstein AR, Samuels L, McRae TD. High-dose and low-dose varenicline for smoking cessation in adolescents: a randomised, placebo-controlled trial. Lancet Child Adolesc Health. 2020 Nov;4(11):837-845. doi: 10.1016/S2352-4642(20)30243-1. Epub 2020 Sep 25. PubMed 32979939 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2011 to primary completion in Jan 2018, 81 months.

Results were first posted in Jun 2018, 5 months after primary completion.

Of 56 phase 4 interventional studies under Smoking Cessation, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 55. This study's 81 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2011
First posted
Mar 11, 2011
StartActual
Apr 2011
Primary completionActual
Jan 2018
CompletionActual
Jan 2018
Results first posted
Jun 28, 2018
Last update
Aug 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01312909
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 11, 2011
Start date
Apr 2011
Primary completion
Jan 2018
Completion
Jan 2018
Results posted
Jun 28, 2018
Last update
Aug 9, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion